MA52292B1 - Compounds and their uses for alleviating symptoms associated with menopause - Google Patents

Compounds and their uses for alleviating symptoms associated with menopause

Info

Publication number
MA52292B1
MA52292B1 MA52292A MA52292A MA52292B1 MA 52292 B1 MA52292 B1 MA 52292B1 MA 52292 A MA52292 A MA 52292A MA 52292 A MA52292 A MA 52292A MA 52292 B1 MA52292 B1 MA 52292B1
Authority
MA
Morocco
Prior art keywords
menopause
symptoms associated
alleviating symptoms
compounds
component
Prior art date
Application number
MA52292A
Other languages
French (fr)
Other versions
MA52292A (en
Inventor
Maud Jost
Glwadys Rausin
Melanie Taziaux
Marie Mawet
Original Assignee
Estetra Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra Srl filed Critical Estetra Srl
Priority claimed from PCT/EP2019/060221 external-priority patent/WO2019202142A1/en
Publication of MA52292A publication Critical patent/MA52292A/en
Publication of MA52292B1 publication Critical patent/MA52292B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un traitement hormonal de substitution, les composés associés et les unités d'emballage associées, pour soulager les symptômes associés à la ménopause qui est basé sur l'administration à un mammifère femelle d'un composant estétrol à une dose quotidienne spécifique, éventuellement en combinaison avec un composant progestogénique. Le traitement bénéficie d'une efficacité statistiquement significative combinée à un profil favorable pour des effets secondaires par comparaison avec des procédés actuellement disponibles pour soulager des symptômes associés à la ménopause.The present invention relates to hormone replacement therapy, related compounds and related packaging units, for alleviating symptoms associated with menopause which is based on the administration to a female mammal of an estetrol component at a specific daily dose , optionally in combination with a progestogenic component. The treatment enjoys statistically significant efficacy combined with a favorable side effect profile compared to currently available methods for alleviating symptoms associated with menopause.

MA52292A 2018-04-19 2019-04-19 Compounds and their uses for alleviating symptoms associated with menopause MA52292B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18168234 2018-04-19
PCT/EP2019/060221 WO2019202142A1 (en) 2018-04-19 2019-04-19 Compounds and their uses for alleviating menopause-associated symptoms

Publications (2)

Publication Number Publication Date
MA52292A MA52292A (en) 2021-02-24
MA52292B1 true MA52292B1 (en) 2022-03-31

Family

ID=62027872

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52292A MA52292B1 (en) 2018-04-19 2019-04-19 Compounds and their uses for alleviating symptoms associated with menopause

Country Status (2)

Country Link
AR (1) AR114799A1 (en)
MA (1) MA52292B1 (en)

Also Published As

Publication number Publication date
MA52292A (en) 2021-02-24
AR114799A1 (en) 2020-10-14

Similar Documents

Publication Publication Date Title
MA47313B1 (en) Her2 antibody subcutaneous formulations
MX2023001705A (en) Compounds and their uses for alleviating menopause-associated symptoms.
MX2023004814A (en) Compounds and their uses for alleviating menopause-associated symptoms.
MA52292B1 (en) Compounds and their uses for alleviating symptoms associated with menopause
Moore et al. Weekly intravenous bortezomib is effective and well tolerated in relapsed/refractory myeloma
FR3073398B1 (en) PENTACYCLIC TRITERPENES IN THE TREATMENT OF ORAL PATHOLOGY
MX2022005596A (en) Dosing regimen for anti-dll3 agents.
MA54511B1 (en) Nutraceutical ophthalmic composition for the treatment of retinal pathologies with a neovascular component
EA202092224A1 (en) COMPOUNDS AND WAYS OF THEIR USE TO RELIEVE THE SYMPTOMS ASSOCIATED WITH MENOPAUSE
BR112022008095A2 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME
Qureshi et al. Hyponatraemia due to hypothyroidism: a rare side effect from pomalidomide
Cabanillas Ipilimumab/tremelimumab
Di Marco Lamotrigine/sodium valproate interaction
Dias Cabergoline/octreotide withdrawal
Loprinzi Key Symptom-Intervention Takeaways from ASCO 2014
Davis Methylprednisolone/triamcinolone
Barton Thalidomide and dexamethasone therapy of myeloma in a patient with previously untreated B‐chronic lymphocytic leukemia
McCurdy First report of exacerbation of lymphomatoid papulosis: 2 case reports
Warren Euprolactinemic galactorrhoea, mastalgia and hypersexuality: case report
Nishikimi Everolimus/sunitinib
Amoako Syndrome of inappropriate antidiuretic hormone secretion and hyponatraemia: case report
Jerome Check et al. COMPLETE RESOLUTION OF THE BURNING MOUTH SYNDROME IN A NORMAL ESTROGENIC WOMAN FOLLOWING TREATMENT WITH AMPHETAMINES
Muruganandam Zoledronic acid
Ceppi Various toxicities: 9 case reports
Gisslinger Development of resistance: 2 case reports